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1. Introduction 
Ellipticine (5-l 1 dimethyl-[6H] -pyridino [4,3] - 
carbazole) and some analogues display an antitumoral 
activity against both experimental nd human tumors 
as well as several other pharmacological properties [ 11. 
The mechanism of the cytotoxic action of these 
drugs is supposedly related to their interaction with 
DNA [2,3]. However, before reaching the nucleus or 
other intracellular sites, these drugs have to interact 
with the cytoplasmic membrane and eventually to 
cross it. It can be observed (fig-l) that elliptictie and 
its 9.methoxy derivative have a net amphipathic 
character, astructural feature which might endow 
these substances with the ability to interact with 
membrane components, especially with phospho- 
Fig.1. Elliptictie and its derivatives. R = : H, ellipticine; OH, 
9-hydroxyellipticine; OCH,, 9-methoxyellipticine; NH,, 
9aminoellipticine. 
lipids. Moreover, it has been postulated that the 
partition coefficient of ellipticine derivatives in an 
octanol-water system could be related to the 
pharmacological properties of these substances [4]. 
Finally, one can assume that the biodisposition and 
the pharmacokinetics of ellipticine derivatives of
therapeutic interest depend on their lipophilicity. 
We therefore have undertaken an in vitro study of 
the interactions of four different ellipticine derivatives 
with phospholipids by means of the monolayer 
technique at the air-water interface. 
Through surface pressure (n) and surface potential 
(Av) measurements, i  is shown that ellipticine and 
9.methoxyellipticine interact with acid phospholipids 
but not with the zwitterions phosphatidylcholine 
and phosphatidylethanolamine. No interaction was 
detected with the dipolar 9-hydroxy-ellipticine 
whereas the dibasic 9.aminoellipticine ispostulated 
to adsorb at water-acidic lipid interfaces. 
2. Experimental 
2.1. Chemicals 
Ellipticine(NSC 71795),911ydroxy-(NSC 210717), 
9.methoxy- and 9aminoellipticine were synthesized 
by Drs N. Dat Xuong and P. Lecointe. The purity of 
these compounds was checked by high pressure liquid 
chromatography [5]. The pK values of these drugs are: 
6.8,6.6,6.8 and 5.0, respectively (J. B. Le Pecq, 
personal communication). Didodecanoylphosphatidyl- 
glycerol was of synthetic origin [6]. Ditetradecanoyl- 
ElsevierlNorth-Holkmd Biomedical Press 155 
Volume 107, number 1 FEBS LETTERS November 1979 
phosphatidylcholine and phosphatidylethanolamine 
(from Escherichia cob) were purchased from Sigma 
(USA). Bovine Brain phosphatidylserine was obtained 
from Calbiochem (USA), and phosphatidic (from egg 
lecithin) from Lipid Products (England). Phosphatidyl- 
inositol and cardiolipin were purified from the mem- 
brane lipids of Microccocus lu teus [ 71, as well as a 
sample of phosphatidylglycerol. A l these compounds 
were pure as indicated by thin-layer chromatography. 
2.2. Methods 
The surface potential was determined with the 
apparatus described in [89]. Owing to the basicity of 
the drugs, the film surface pressure was measured by 
means of a floating barrier [9]. Experimental con- 
ditions were identical to those in [8,9]. The lipids 
were spread from chloroform/methanol 5/l (v/v) 
solutions. Reproducibility of ?T and Au determina- 
tions (carried out at 20°C) were * 0.2 mN .m-’ and 
+ 10 mV respectively. 
2.3. Procedure 
Unless otherwise stated, drug-lipid interactions 
were studied as follows: concentrated water solu- 
tions (lob3 M, pH 5) of the drugs were injected step- 
wise under films of phospholipids compressed at
initial n = 5 mN .m-l, R and Au being measured at 
equilibrium, after 1 min stirring of the subphase at 
each step. In order to ensure a good Au recording 
[8], the subphase was 10 mM NaCl at pH 6. At this 
pH and ionic strength, phosphatidylcholine and phos- 
phatidylethanolamine on one hand, acidic lipids on 
the other hand can be regarded as zwitterions [lo] 
and anions [7,10,11], respectively. Ellipticine and its 
9-hydroxy- and 9-methoxy-derivatives arenearly 
totally protonated. As shown below, NaCl at 10 mM 
does not prevent he drug-lipid interactions when 
they occur. 
3. Results 
3 .l . Influence of the lipid structure 
It should be noted first that the drugs alone are 
slightly surface active. The presence of ellipticine at 
10” M in the trough decreased the water surface 
tension by 0.5 mM .m-’ and increased Au by 75 mV 
156 
(insert, fig.2). Nevertheless, no film could be obtained 
by spreading the drug at the water surface. 
Injecting ellipticine under films of phosphatidyl- 
choline or phosphatidylethanolamine to reach 1 O-’ M 
resulted in small n increases of 1 and 4 mN .m-’ and 
in Au increases of 75 mV (from 2 1 O-285 mV) and 
50 mV (from 330-380 mV), respectively (fig.2). 
Modifying the initial film pressure or the subphase 
ionic strength did not significantly alter these results. 
A completely new picture was observed with the 
acidic lipids tested. As can be seen in fig.2, adding 
ellipticine to the subphase r sulted in a considerable 
Au jump. It is of note that at saturation, each system 
stabilized at the same potential of 480 k 5 mV. A 
large B increase was observed, epending on the nature 
of the lipid (frg.2). The most important effect was 
found for phosphatidic acid and cardiolipin (An 2/ 
2 1 mN .m-‘), two lipids which potentially bear two 
negative charges. Tests carried out with phosphatidyl- 
glycerol but at pH 7.2 (phosphate buffer) gave iden- 
tical results. Control experiments carried out with the 
same lipid compressed atinitial surface pressures of
lo,17 and 26 mN .m-’ gave similar esults, namely 
large n increases of An = 26,19 and 10 mN .m-' , 
respectively and Au jumps of about 300 mV,_to reach 
the same final value of 480 mV. 
From 71 and Au data, the drug concentration 
required to obtain the halfeffect appeared to be 
< 10” M, a result which indicates avery high affinity 
of the drug for acidic lipids. 
3 2. Influence of the drug structure 
Since the interaction of ellipticme with acidic 
lipids appeared to be non-specific, additional tests 
were carried out with phosphatidylglycerol and phos- 
phatidylinositol nly. 9-Methoxyellipticine interacting 
with didodecanoylphosphatidylglycerol gave results 
nearly identical to those obtained with ellipticine, in 
terms of both IT and Au, while the 9-hydroxyellipticine, 
at 1 Oe5 M, raised n and Au by 1 mN .m-’ and 120 mV, 
respectively. These values are not very different from 
those measured for the ellipticine-phosphatidyl- 
choline system (fig.2). Testing 9-amino-ellipticine 
against phosphatidylinositol gave rise to a small 71 
increase of 1 mN m-’ but to a Au jump of 180 mV 
(from 130-3 10 mV). With phosphatidylglycerol from 
M. luteus, a similar Au jump of 170 mV was detected, 
but in this case 7~ decreased by 3 mN m-l. 
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F&Z. Changes in r and Av for films of various lipids compressed at initial n = 5 mN .m-’ on a 10ea M NaCl subphase (pH 6), as a 
function of the concentration of ellipticine in the subphase. Phosphatidylchohne (A)(PC); phosphatidylethanolamme (*) (PE); 
pho~hatidy~ly~rol (0) (PG); phosphatidylserhre (*) BS); phosphatidy~nositol (*) (PI); cardiolipin (0) (CL); phosphatidic acid 
t.) (PA). 
3.3. Competition between ellipticine and cations 
Assays were carried out by stepwise injection 01 
concentrated salt solutions (1 M, pH 6) under films of 
didodecanoylphosphatidylglycerol compressed atan 
initial 10 mN m-l, ellipticine remaining constant at 
10” M. Results are presented in fig.3 together with 71 
and Av data obtained for the same lipid molecular 
area but without drug in the subphase. As can be 
seen,Na’ had no effect on the drug-lipid interactions. 
rr and Av vahres remained unch~ged upon addition 
of NaCl and different from those observed in the 
absence of drug. The same was found with Ca” up 
to 10” M, At 10” M, Av dropped to 280 mV, 
similar to that observed in the absence of drug (270 
mV). However, the n remained nearly constant at 
12 mN mm-l, well above the 1 mN m-r found for the 
lipid without drug in the subphase. While Av points 
to a competition between the drug and Ca2’ for the 
phosphate groups, r still accounts for the presence 
of the drug within the film. This complex system 
deserves a more detailed study to be fully elucidated. 
4. Discussion 
Ellipticine and its 9-methoxy derivative display a 
very high affinity for acidic phospho~pids. The n 
increases which result from the drug-lipid interac- 
tions are too large to be simply due to an adsorption 
of the drugs at the water-lipid interface. More likely, 
it is suggested that such pressure increases originate 
from an intercalation of the drugs between the lipid 
molecules, the @ group mteracting with the phos- 
157 
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F&S. Changes in surface potential (full symboIs) and surface pressure (open symbols) measured for films of didodecanoylphos- 
phatidylglycerol as a function of the concentration of NaCl and CaCl, in the subphase, in the presence of ellipticine at 10.’ M 
(~,a) or in its absence (0.0). 
phate function and the aromatic moiety being in con- 
tact with the lipid acyl chains. Accordingly, the very 
high and constant surface potential observed at satura- 
tion for each lipid might account for a strong PO- . . . 
NH+ dipole, similarly oriented in each system. 
fn contrast, the zwitterions pbosphat~dy~~ho~~e 
and phosphatidy~e~ano~am~e ppear to be very 
poor ligands, at least at the pH 5-6 considered. n and 
Au data measured for these two lipids are similar to 
those recorded in the absence of lipid at the water 
surface and they could simply originate from the 
presence of the drug in the proximity of the water- 
lipid interface. Nevertheless while some penetration 
of the drug within films of these lipids cannot be 
completely excluded, it should be limited to a few 
drug molecules only, owing ta the strong repulsive 
forces and therefore to the energy increase v&ich 
would rapidly generate at the interface [121. Like- 
wise, n and Av data for dipolar 9.hydroxy~~iptic~e 
do not allow us to conclude any significant interaction 
with p~ospha~dy~~~cero~~ The lack of interaction in 
this case can be related to the presence of the hydroxyl 
group, a polar function which is very difficult to 
bring into a hydrophobic lipid environment (131. 
R and Av data measured for dibasic 9-amino- 
ehipticine are similar to those recorded for the methyl 
ester of lysine, a molecule which has been shown to 
adsorb strongly at phosphatidylglycerol-water inter- 
faces [9]. Thereby, the hypothesis of an adsorption 
of the drug at water-acidic lipid interfaces can be 
envisaged, the molecule interacting with two phos- 
phate groups in the interface plane. 
Another interesting finding is the high Ca** concen- 
tration which is required for destabilizing the ellipti- 
tine-lipid interactions, This cation is known to have 
a very high affinity for the phosphate group of acidic 
phospho~pids [14] and to play a very important role 
in stabilizing the membrane structure [151. Our data, 
suggest that ellipticine could compete with Cap for 
the phosphate Iipid sites in membranes. 
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The interaction of ellipticine with acid phospho- 
lipids could be one factor among several which are 
responsible for its complex pharmacological action, 
since the drug concentration at which the lipid layer 
is saturated (- 10” 14) is close to those necessary for 
saturating DNA [I] or microsomes [ 161, two other 
biological structures displaying a strong affinity for 
elhpticine. The binding of the drug to microsomal 
lipids which contain -2.54% of acid phospholipids 
(phosphatidylserine and phosphatidylinositol) [ 171 
is probably of great pharmacological significance: 
the metabolic transformation of the drug is carried 
out in the microsomal machinery [ 181 and ellipticine 
is the most potent inhibitor of the cytochrome P-450 
reduction [16,19]. It has been shown [20] that the 
removal of the lipids from the rat liver microsomes 
decreases the apparent affinity of ellipticine for cyto- 
chrome P-450 by a factor of -10. 
The biological action of ellipticine and 9-methoxy- 
ellipticlne might derive from perturbations in the 
organization and the fluidity of the lipid matrix in 
membranes. Such perturbations might either be 
directly responsible for the loss of some essential cell 
function or lead to the secondary disentanglement of 
reactive membrane sites and their subsequent expo- 
sure to extrinsic agents. 
At last, these results suggest hat some lipids can 
serve as a reserve binding pool for elllpticine and some 
of its hydrophobic derivatives. This observation must 
be taken into account for explaining some pharmaco- 
kinetics data [21,22]. 
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